Gastrointestinal Cancer

Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?

Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?

[OncoTargets and Therapy] Although first-line therapy is effective, relapse is common; but many patients are good candidates for second-line therapy. This report reviews current published data on second-line therapies for advanced pancreatic cancer.

Computer-Aided Colonoscopy Reliably Identifies Small Polyps

Computer-Aided Colonoscopy Reliably Identifies Small Polyps

Researchers evaluated the performance of real-time CAD with endocytoscopes among 791 consecutive patients undergoing colonoscopy.

Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer

Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer

By

Seeking to determine if breath tests could be used to diagnose pancreatic cancer, researchers identified breath volatile organic compounds (VOCs) that may indicate presence of the disease.

Navigating Patients With Gastrointestinal Cancer

Navigating Patients With Gastrointestinal Cancer

By

The unique challenges that face both oncology nurse navigators specializing in gastrointestinal cancer and patients with these diseases are reviewed in a presentation at the 2018 ONA Navigation Summit.

Multimodal Follow-up Improved Postradiotherapy Sexual Health in Lower GI, Gynecologic Cancers

Multimodal Follow-up Improved Postradiotherapy Sexual Health in Lower GI, Gynecologic Cancers

By

Researchers sought to determine the effectiveness of a multimodal continuity of care program for women receiving radiation therapy for gynecologic or lower GI cancers. Their findings were presented at the 2018 ONS Annual Congress.

Hope, Optimism Reduce Psychological Distress in Advanced Cancer

Hope, Optimism Reduce Psychological Distress in Advanced Cancer

By

A cross-sectional analysis evaluated the impact of hope and optimism on different facets of psychological distress among patients with advanced melanoma, colorectal, lung, or gastrointestinal cancers.

Clinicopathological Features and Prognosis in Elderly Gastric Cancer Patients: A Retrospective Cohort Study

Clinicopathological Features and Prognosis in Elderly Gastric Cancer Patients: A Retrospective Cohort Study

[OncoTargets and Therapy] A retrospective study assessed patients with gastric cancer, identifying disease characteristics more prevalent in elderly patients and the effect on prognosis for these patients.

Influence of Alcohol Consumption on Survival Outcomes of Hepatocellular Carcinoma

Influence of Alcohol Consumption on Survival Outcomes of Hepatocellular Carcinoma

By

Results of the prospective CHANGH study demonstrate the effect of alcohol consumption on early diagnosis, management, and overall survival for patients with hepatocellular carcinoma.

Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers

Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers

By

Sexual impairment is frequently associated with breast and pelvic cancers, but patients with digestive cancer also experience this effect. In this study, researchers assessed sexual activity, dysfunction, sexual quality of life, and need for oncosexology care among patients with gastrointestinal cancers.

Higher Socioeconomic Status Leads to Improved Survival Outcomes in Anal Cancer

Higher Socioeconomic Status Leads to Improved Survival Outcomes in Anal Cancer

By

A multivariable analysis revealed how median household income influences cancer-specific and overall survival among patients with squamous cell carcinoma of the anus.

Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy

Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy

By

At $225 million per system, the precision of proton beam radiotherapy is not necessarily overshadowing its high costs. Yet ongoing studies seek to determine how this technology fits into current treatment regimens for prostate, breast, and other cancers.

Cachexia Not Improved With Celecoxib Plus Megestrol vs Megestrol Alone

Cachexia Not Improved With Celecoxib Plus Megestrol vs Megestrol Alone

By

Double-blind phase 3 study evaluated the effect of megestrol combined with celecoxib vs monotherapy on cachexia in patients with gastrointestinal cancer.

Preoperative Treatment for Gastric Cancer Varies by Race, Ethnicity

Preoperative Treatment for Gastric Cancer Varies by Race, Ethnicity

By

Researchers conducted a retrospective study of US patients with gastric cancer to determine what factors influenced the use of preoperative chemotherapy in this patient population.

Comparative Study of Clinical Efficacy Using Three-dimensional and Two-dimensional Laparoscopies in the Treatment of Distal Gastric Cancer

Comparative Study of Clinical Efficacy Using Three-dimensional and Two-dimensional Laparoscopies in the Treatment of Distal Gastric Cancer

[OncoTargets and Therapy] This study investigated the safety and feasibility of 3D laparoscopic-assisted radical gastrectomy for distal advanced gastric cancer vs 2D laparoscopic surgery, results of this study have shown.

Recognizing Reduced Dietary Intake in Hospitalized Patients With Colorectal Cancer

Recognizing Reduced Dietary Intake in Hospitalized Patients With Colorectal Cancer

By

Analysis revealed factors that contribute to reduced dietary intake among hospitalized patients with colorectal cancer.

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

By

Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.

Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence

Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence

By

Study results presented at the 2018 Gastrointestinal Cancers Symposium demonstrated the sensitivity and specificity of the CMx biomimetic platform, a novel approach to detecting CRC and precancerous lesions that could improve screening rates.

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib

By

Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer

By

In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.

Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy

Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy

[Journal of Thoracic Disease] A randomized study investigated whether an mERAS protocol could result in improved recovery of aged patients with esophageal cancer undergoing esophagectomy.

Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer

Overall Survival Prolonged With HIPEC + Cytoreductive Surgery for Gastric Cancer

By

Data presented at the 2018 Gastrointestinal Cancers Symposium compared overall survival with cytoreductive surgery (CRS) alone for patients with gastric cancer and peritoneal carcinomatosis vs treatment with HIPEC plus CRS.

Better Postoperative Outcomes With RAMIE for Esophageal Cancer

Better Postoperative Outcomes With RAMIE for Esophageal Cancer

By

Research presented at the 2018 Gastrointestinal Cancers Symposium described benefits seen with RAMIE vs chemotherapy or chemoradiotherapy plus OTE for esophageal cancer.

FDA Approves Biosimilar Trastuzumab-dkst for Breast and Stomach Cancers

FDA Approves Biosimilar Trastuzumab-dkst for Breast and Stomach Cancers

Ogivri was granted FDA approval to treat HER2 breast and gastric or gastroesophageal junction adenocarcinoma cancers.

PPI-Gastric Cancer Link Remains After <i>H. Pylori</i> Eradication

PPI-Gastric Cancer Link Remains After H. Pylori Eradication

Increased risk seen in H. pylori-infected subjects who received eradication therapy

Symptoms, Economic Burden Reduce QoL in Gastrointestinal Cancer Survivors

Symptoms, Economic Burden Reduce QoL in Gastrointestinal Cancer Survivors

By

A cross-sectional survey revealed the impact of symptoms and economic burden on quality of life for survivors of gastrointestinal cancer.

Childhood-Onset IBD May Increase Adult Cancer Risk

Childhood-Onset IBD May Increase Adult Cancer Risk

Researchers think chronic inflammation in gastrointestinal tract may increase the future risk of gastrointestinal cancers, lymphoid neoplasms, and skin cancer.

CAR, PNI Levels Correlate with Outcomes in Pancreatic Cancer

CAR, PNI Levels Correlate with Outcomes in Pancreatic Cancer

By

An association was found between low PNI/high CAR levels and poor outcomes in operable pancreatic ductal adenocarcinoma, even in patients who undergo curative resection.

Risk of Some Cancers Higher in Women With a History of Periodontal Disease

Risk of Some Cancers Higher in Women With a History of Periodontal Disease

By

A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.

Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities

Increases in Liver Cancer Incidence Influenced by Higher Rates of Comorbidities

A new report from ACS describes trends in liver cancer and the factors influencing the ongoing increase in incidence, particularly higher rates of HCV infection, obesity, and type 2 diabetes.

No Serious HRQOL Decline With FOLFOXIRI/Bevacizumab

No Serious HRQOL Decline With FOLFOXIRI/Bevacizumab

By

Study compared FOLFOXIRI/bevacizumab and FOLFOX/bevacizumab in patients with metastatic colorectal cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs